Correspondence 0001213900-24-101772 from Radiopharm Theranostics Ltd (RADX, RDPTF) (CIK 0001949257) (RADX)
Radiopharm Theranostics Ltd (RADX, RDPTF) (CIK 0001949257)
Date: Nov. 25, 2024 · CIK: 0001949257 · Accession: 0001213900-24-101772
AI Filing Summary & Sentiment
File numbers found in text: 001-41621
Letter
November 25, 2024
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Gary Newberry
Kevin Vaughn
Lauren Hamill
Suzanne Hayes
RE: Radiopharm Theranostics Limited
Registration Statement on Form 20-FR12B
File No 001-41621
Ladies and Gentlemen:
The undersigned registrant hereby requests that the effectiveness of the above captioned Registration Statement on Form 20-F, initially filed with the U.S. Securities and Exchange Commission on February 13, 2023, as thereafter amended, be accelerated so that it will be made effective at 9am Eastern Time on November 27, 2024, or as soon thereafter as practicable, pursuant to Section 12(d) and Rule 12d1-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
The undersigned registrant hereby requests accelerated effectiveness in connection with the completion of the registration of the undersigned registrant’s ordinary shares as represented by American Depositary Shares, under Section 12(b) of the Exchange Act, and planned listing on the Nasdaq Capital Market.
Once the Registration Statement has been declared effective, please confirm it with our counsel, Rimôn Law Pty Ltd, by emailing Andrew Reilly at andrew.reilly@rimonlaw.com.
Very truly yours,
Radiopharm Theranostics Limited
Show Raw Text
CORRESP
1
filename1.htm
November 25, 2024
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Gary Newberry
Kevin Vaughn
Lauren Hamill
Suzanne Hayes
RE:
Radiopharm Theranostics Limited
Registration Statement on Form 20-FR12B
File No 001-41621
Ladies and Gentlemen:
The undersigned registrant hereby requests that the effectiveness of
the above captioned Registration Statement on Form 20-F, initially filed with the U.S. Securities and Exchange Commission on February
13, 2023, as thereafter amended, be accelerated so that it will be made effective at 9am Eastern Time on November 27, 2024, or as soon
thereafter as practicable, pursuant to Section 12(d) and Rule 12d1-1 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”).
The undersigned registrant hereby requests accelerated effectiveness
in connection with the completion of the registration of the undersigned registrant’s ordinary shares as represented by American
Depositary Shares, under Section 12(b) of the Exchange Act, and planned listing on the Nasdaq Capital Market.
Once the Registration Statement has been declared effective, please
confirm it with our counsel, Rimôn Law Pty Ltd, by emailing Andrew Reilly at andrew.reilly@rimonlaw.com.
Very truly yours,
Radiopharm Theranostics Limited
By:
/s/ Riccardo Canevari
Riccardo Canevari
Chief Executive Officer and
Managing Director